Probi completed the first commercial production batches of Blis K12 at its U.S. manufacturing site. The company was able to eliminate the need for dairy milk products in the formulation as well.
Probi (Lund, Sweden) completed the first commercial production batches of a dairy-free Streptococcus salivarius called Blis K12 at its U.S. manufacturing site. The new Blis strains support the natural immune defense and help reduce the risk of mouth and throat infections. Since its partnership with New Zealand-based Blis Technologies Ltd., Probi now manufactures Blis strains at its fermentation facility in Redmond, WA. The new strains will shortly be offered to Probi customers worldwide.
“The technology transfer of Blis strains to Probi has gone smoothly and we have been able to make very rapid progress due to our sizable investments in fermentation technology and upgrades to our analytical capability,” said Steve Preston, Probi’s head of fermentation, in a press release. “Furthermore, as part of our high throughput screening program for culture media optimization, we have been able to completely eliminate the need for dairy (milk) products in the formulation. We believe this is very helpful for customers seeking to produce allergen free probiotic products.”